Pasireotide in Acromegaly: An Overview of Current Mechanistic and Clinical Data | Zendy

Susan L. Samson | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Pasireotide in Acromegaly: An Overview of Current Mechanistic and Clinical Data

Author(s) -

Susan L. Samson

Publication year - 2015

Publication title -

neuroendocrinology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.493

H-Index - 101

eISSN - 1423-0194

pISSN - 0028-3835

DOI - 10.1159/000381460

Subject(s) - acromegaly , pasireotide , medicine , somatostatin , somatostatin receptor 2 , octreotide , lanreotide , endocrinology , somatostatin receptor , pegvisomant , neuroendocrine tumors , somatotropic cell , oncology , hormone , growth hormone

Acromegaly is an insidious neuroendocrine disorder caused by hypersecretion of growth hormone (GH) by a somatotroph adenoma. Somatostatin receptor ligands (SRLs) are recommended as first-line medical therapy in patients for whom surgery has failed or is contraindicated. There are 5 known somatostatin receptor subtypes (SSTRs), 2 of which, i.e. SSTR2 and SSTR5, are expressed by a majority of somatotroph adenomas. The currently available SRLs, i.e. octreotide and lanreotide, primarily bind to SSTR2. Pasireotide (SOM230) is a new multireceptor-targeted SRL which has a broader binding profile and an increased affinity for SSTR1, 2, 3, and 5.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research